Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

QTTB

+ Watchlist+ Portfolio

Q32 Bio Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$8.63
52-Week Range
$1.91 – $23.57
Market Cap
$255.25M
P/E (TTM)
2.37
EPS (TTM)
3.60
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.89
PEG Ratio
—
Return on Equity
23.96%
Return on Assets
6.47%
Gross Margin
70.34%
Operating Margin
34.20%
Profit Margin
60.02%
Current Ratio
56.34
Debt/Equity
0.02
Total Debt
$5.12M
Free Cash Flow
$19.48M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-29.21M

Market Snapshot

About

Q32 Bio is a clinical-stage biotechnology company developing therapies targeting the complement pathway for immune-mediated diseases. The company focuses on conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Q32 Bio uses a precision approach to modulate specific complement components, aiming for targeted efficacy with reduced side effects compared to broader immunosuppression.